Research Notes

Stay informed with the most recent market and company research insights.

A man sitting at a table with a glass of orange juice.

Research Notes

US marketing partner continues to improve

Aroa Biosurgery
3:27pm
March 22, 2024
ARX’s US marketing partner TelaBio reported an in line CY23 result and provided CY24 revenue growth guidance of ~30% which was in line with consensus. This is a positive read through for ARX and gives us confidence that average revenue growth of 20% pa can be achieved for the next three years. No changes to forecast or valuation. Add maintained.

Certainly didn’t waste a crisis

Webjet
3:27pm
March 21, 2024
The key takeaway from the WebBeds Strategy Day is that management is confident of delivering A$10bn of TTV by FY30 via organic means. Importantly, this will be achieved while delivering an industry leading EBITDA margin of 50% and strong cashflow conversion of 90-110%. Whilst we have only made slight upgrades to our forecasts reflecting WEB’s FY30 targets, the potential upgrades for consensus will be much more material. The next update from WEB is likely at its FY24 result on 22 May when we expect it to release its capital management policy given its strong balance sheet. With a double-digit earnings growth profile out to FY30, we maintain an Add rating.

Activity air-pocket, with strong long-run demand

Brickworks
3:27pm
March 21, 2024
BKW continues to paint a relatively sanguine picture, with building products expected to see some short-term weakness. The property portfolio has declined in value as a result of a 100bps increase in cap rates to 5.1%, despite continued strength across the underlying operating markets. Longer term, management remains firmly of the opinion that Australia is on the cusp of a property boom, with record immigration levels and population growth exacerbating an already chronic housing undersupply issue. The industrial portfolio is expected to continue growing rental income, with the business outlining a path to double rent through continued development and passing rental growth. Our view remains largely unchanged, with the short to medium outlook remaining relatively soft, which will see the group strategy shifting from investment to cashflow generation. This sees modest earnings growth through FY25, hence our Hold recommendation.

No surprises ... now a waiting game for ACCC decision

Sigma Healthcare Ltd
3:27pm
March 21, 2024
SIG posted its FY24 result which came in at the top end of EBIT guidance (pre-merger costs of $8.2m). As we expected there was limited commentary around the ACCC process, with SIG making its submission in February and public consultation starting from 8 March. We don’t expect a decision until the end of CY24. Given our view on the timing of the ACCC announcement we have delayed the incorporation of the CWG business into our model by six months. After rolling our model forward and including CWG from 31 January 2025 our target price has increased to $1.14 (was $1.07). As the share price is within 10% of the new target we move to a Hold (previously Add) recommendation.

Growing the Swiss footprint

Sonic Healthcare
3:27pm
March 20, 2024
Sonic Healthcare (SHL) is acquiring Switzerland-based Dr Risch laboratory group (Dr Risch) for CHF117m (A$202m), including CHF30m (A$52m) in scrip, with the balance funded via existing CHF cash and debt. Dr Risch employs c650 staff across 13 laboratories and has a lab in Liechtenstein, with a full-range offering of routine and specialty laboratory testing and combined annual turnover of cCHF102m (cA$176m). The deal is expected to close by 31 Mar-24, with the transaction EPS accretive from CY25 and ROIC positive once synergies from multiple areas of infrastructure and operations are achieved. We have adjusted FY24-26 estimates, with our target price increasing to A$34.94 (from A$34.05). Add rating maintained.

+50% margins through the cyclical low ain’t bad

New Hope Group
3:27pm
March 19, 2024
Another typically solid 1H result from NHC with few surprises outside of the dividend which beat our cautious estimate. All guidance was re-affirmed, with higher volumes to support 2H cost reduction. NHC’s defensive attributes – cash margins, balance sheet, steady dividends – appear to support lower volatility relative to more leveraged peers. Maintain Hold as NHC trades within 10% of fair value. A forecast 7-8% yield offers solid compensation as investors await the next upswing.

Putting the customer first

Myer
3:27pm
March 18, 2024
Myer Holdings (ASX: MYR) operates the largest chain of premium and mid-range department stores in Australia. The business was founded 124 years ago, but even after the emergence of the suburban shopping centre and the rise of multicategory ecommerce sites, Myer has managed not just to remain relevant but is performing strongly on an active program of reinvention. Sales last year were the highest since 2005, underpinned by over 20% online penetration and more than 4m active members in its loyalty program. The balance sheet is in good shape with over $200m in net cash (excluding leases) and Myer is back to paying dividends. A new CEO, Olivia Wirth, takes the reins in June, looking to replicate with MYER one her success with the Qantas Frequent Flyer loyalty program.

Re-basing expectations

True North Copper
3:27pm
March 15, 2024
The CCP mining study details a value accretive project offering material positive cash flows from late 2024. The mining re-start will now mobilise. Execution of the CCP re-start to plan is company-defining in 2024 as TNC has an opportunity to achieve self-funding status and allay market fear of liquidity risk. We think the current share price ascribes no value to the CCP’s 4.6 year reserves, projected cash flows or mine life upside. Upside leverage to execution success is significant. Mt Oxide’s true blue-sky potential also appears overlooked. Potential returns from 8cps are substantial although we think investors do require greater risk tolerance. Demonstrating commerciality late 2024 is key.

Updating for Q1, Suncorp Bank, and 16.5% AmBank

ANZ Banking Group
3:27pm
March 14, 2024
We update our modelling for Q1 performance, inclusion of Suncorp Bank acquisition (given completion looks increasingly likely), and sale of 16.5% AmBank. Meaningful forecast upgrades because of incremental earnings from the SB acquisition now included in our modelling. We forecast earnings decline in FY24F while assumed full year inclusion of SB helps alleviate further declines in FY25F. 12 month target price lifts 9% to $26.83/sh. HOLD retained at current prices.

Implements on market buyback

Clinuvel Pharmaceuticals
3:27pm
March 14, 2024
CUV have announced an on-market buy back of approximately 3% of the shares on issue. We had been calling out for capital management and viewed this was necessary given the significant cash stockpile whilst sitting on multi-year lows. While several issues continue to present an overhang for the stock in our view, we view this as a step in the right direction. We make no changes to our valuation at this stage however given the weakness following our last note, we move back to an Add recommendation.

News & Insights

Michael Knox, Chief Economist, reveals how the OECD and RBA’s outdated assumptions about global trade fail to account for China’s Marxist-Leninist economic strategies.

This morning, I was asked to discuss Sarah Hunter’s presentation from yesterday. Sarah, the Assistant Governor and Chief Economist at the Reserve Bank of Australia (RBA), delivered a detailed and competent discussion on the conventional view of tariffs’ impact on the international economy. She highlighted that tariffs typically increase inflation and reduce economic output, a perspective echoed by the OECD in a similar presentation overnight. Sarah’s analysis focused on the potential shocks tariffs could cause, particularly their effects on GDP and inflation.

Drawing on my experience as an Australian trade commissioner and my work in Australian embassies, I found her presentation particularly interesting. My background allowed me to bring specialist knowledge to the conversation, which I believe gave me an edge. Notably, I observed that the RBA seems to lack analysts closely tracking individual policymakers in the Trump administration, such as Scott Bessent, whose views on tariffs and competition differ from the general assumptions. The conventional view assumes a world of perfectly competitive countries adhering to international trade rules and unlikely to engage in conflict—a scenario that doesn’t align with the current global trade environment, especially between China and the United States.

China, operating as a Marxist-Leninist economy, aims to dominate global markets by building monopolies in areas like rare earths, nickel, copper, and other base metals. It maintains a managed exchange rate, despite promises to the International Monetary Fund for a freely floating currency. If China allowed its currency, the RMB, to float, it would likely appreciate significantly, increasing imports and reducing its trade surplus. This would create a more balanced international trade environment, potentially reducing the need for other countries to impose tariffs. However, major institutions like the OECD and RBA seem to misjudge the nature of this trade shock, relying on outdated assumptions about global trade dynamics.

The international community also appears to overlook specific U.S. policy intentions, such as those articulated by figures like Peter Navarro and Scott Bessent. The U.S. aims to use tariffs selectively to bolster industries like pharmaceuticals, precision manufacturing, and motor vehicles. This misunderstanding leads public institutions to perceive unspecified risks, as reflected in Sarah’s otherwise able presentation. Because the RBA and similar institutions view the world as fraught with undefined risks, they are inclined to keep interest rates low, responding to perceived threats rather than an equilibrium model.

Interestingly, data from the U.S. economy contradicts the expected negative impacts of tariffs. The Chicago Fed National Activity Indicator, a reliable gauge of economic growth since the 2008 financial crisis, shows U.S. growth above the long-term trend for the first four months of this year. This suggests resilience despite tariff-related shocks. Ideally, growth will slow later this year, prompting the Federal Reserve to cut rates, facilitating a soft landing and a decline in the U.S. dollar to boost global commodity prices. However, this nuanced outlook wasn’t evident in yesterday’s presentation.

Moreover, the anticipated rise in U.S. inflation due to tariffs isn’t materialising. Scott Bessent recently noted that U.S. CPI inflation is lower than expected, with core inflation shown as the (16% trimmed mean) at 3% for the past two months . Core inflation  excluding  food and energy CPI  is only at 2.8%. This suggests that Chinese suppliers are absorbing tariff costs to maintain market share, rather than passing them on as higher prices. Recent Chinese data supports this, showing a slight decline in manufacturing confidence and coal consumption, indicating reduced factory output and electricity use. This points to a modest slowdown in China’s economy. So far the expected negative effects on U.S. prices and output are not occurring.

In summary, the fears expressed by institutions like the RBA and OECD about the Trump administration’s trade policies appear overstated. The U.S. economy is not experiencing the predicted declines in output or increases in inflation. While these effects may emerge later, the current data suggests that the risks are not as severe as anticipated, highlighting a disconnect between theoretical models and real-world outcomes.

Read more
Michael Knox outlines the economic outlook for growth and inflation in the U.S., the Euro area, China, India, and Australia, drawing data from the International Monetary Fund, the Congressional Budget Office, European sources, and his own analysis for Australia.

Today, I’m presenting the first page of my updated presentation, which focuses on GDP growth and inflation expectations for major economies. Before diving into that, I want to clarify a point about U.S. trade negotiations that has confused some media outlets.

In the previous Trump Administration ,there was single trade negotiator, Robert Lighthizer, held a cabinet position with the rank of Ambassador. This time, to expedite negotiations and give them more weight, Trump has appointed two additional cabinet-level officials to handle trade talks with different regions. For Asian economies, Scott Bessent and Ambassador Jamison Greer, who succeeded Lighthizer and previously served on the White House staff, are managing negotiations, including those with China. For Europe, Howard Lutnick, the Commerce Secretary, and Ambassador Greer are negotiating with the European Trade Representative. When the EU representative visits Washington, D.C., they meet with Lutnick and Greer, while Chinese or Japanese representatives engage with Bessent and Greer.

In my presentation today, I’m outlining the economic outlook for growth and inflation in the U.S., the Euro area, China, India, and Australia, drawing data from the International Monetary Fund, the Congressional Budget Office, European sources, and my own analysis for Australia.

For the U.S., the best-case scenario is a soft landing, with growth slowing but remaining positive at 1.3% this year and rising to 1.7% next year. This slowdown allows the Federal Reserve to continue cutting interest rates, leading to a decline in the U.S. dollar. This in turn ,triggers a recovery in commodity prices. These prices have stabilized and are now trending upward, with an expected acceleration as the dollar weakens.

U.S. headline inflation is projected to be just below 3% next year, with higher figures this year driven by tariff effects.



Global Economic Perspective

In the Euro area, growth is accelerating slightly, from just under 1% this year to 1.2% next year, with inflation expected to hit the 2% target this year and dip to 1.9% next year.

China’s GDP growth is forecast  at 4% for both this year and next, a step down from previous 5% rates, reflecting a significant slump in domestic demand and very low inflation  Chinese Inflation is only  :   0.2% last year, 0.4% this year, and 0.9% next year.  Despite a massive fiscal push, with a budget deficit around 8% of GDP, China’s debt-to-GDP ratio is rising faster than the U.S.. Yet this is  yielding more modest  domestic growth.

India, on the other hand, continues to outperform, with 6.5% GDP growth last year, 6.2% this year, and  6.3%  next year, surpassing earlier projections.

Read more
In our International Reporting Season Review, we provide an overview of the March 2025 quarterly results season for companies in the Americas, Europe and Asia.

Positive earnings surprise

In our International Reporting Season Review, we provide an overview of the March 2025 quarterly results season for companies in the Americas, Europe and Asia. For all the volatility in markets caused by US trade policy, the results were positive. For all the 187 high profile and blue-chip companies in our International Watchlist, the median EPS beat vs consensus was 3.2%, nearly twice that recorded in the December quarter (1.8%). 37% of companies exceeded consensus EPS expectations by more than 5% and only 9% missed by more than 5%. Communication Services was the most positive sector, led by Magnificent 7 companies Alphabet and Meta Platforms. The median EPS beat in that sector was 13%. Consumer Discretionary was the biggest disappointment (though only a mild one) with EPS falling 0.6% short of analyst estimates on a median basis.

Alphabet and Meta among the best performers

Across our Watchlist, some of the best performing stocks in terms of EPS beats were Alphabet, Boeing, Uniqlo-owner Fast Retailing, Meta Platforms, Newmont and The Walt Disney Company. Notable misses came from insurance broker Aon, BP, PepsiCo, Starbucks, Tesla and UnitedHealth. The latter saw by far the worst share price performance over reporting season, its earnings weakness compounded by the resignation of its CEO and the launch of a fraud investigation by the Department of Justice. British luxury fashion label Burberry had the best performing share price as it gains traction in its turnaround plan.

Tariffs were the main talking point (of course)

The timing of President Trump’s ‘Liberation Day’ on 2 April, just before the March quarter results started rolling in, guaranteed that US tariffs would be the main talking point throughout reporting season. Most companies took the line that higher tariffs presented a material risk to global growth and inflation. The rapidly shifting sands of US trade policy mean the impact of tariffs is highly uncertain. This didn’t stop many companies from trying to estimate the impact on their profits. This ranged from the very precise ($850m said RTX) to the extremely vague (‘a few hundred million dollars’ hazarded Abbott Laboratories). The rehabilitation of AI as a systemic driver of long-term value was a key theme of reporting season, with many companies reporting what Palantir Technologies described as an ‘unstoppable whirlwind of demand’ and others indicating an increase in planned AI investment. The deterioration in consumer confidence was another key talking point, though most companies could only express concern about a possible future softening in demand rather than any actual evidence of a hit to sales.

Our International Focus List continues to outperform

In this report, we also report on the performance of the Morgans International Focus List, which is now up 25.3% since inception last year, outperforming the benchmark S&P 500 by 20.4%.


Morgans clients receive exclusive insights such as access to our latest International Reporting Season article.

Contact us today to begin your journey with Morgans.

      
Contact us
      
      
Find an adviser
      
Read more